Terns Pharmaceuticals Inc

Stock Chart, Company Information, and Scan Results

$32.81(as of Dec 8, 4:06 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Terns Pharmaceuticals Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$32.81
Ticker SymbolTERN
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees59
CountyUSA
Market Cap$2,644.7M

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals Inc In Our Stock Scanner

As of Dec 09, 2025
example chart graphic
Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.